Japanese
English
- 有料閲覧
- Abstract 文献概要
- 1ページ目 Look Inside
- 参考文献 Reference
要旨 潰瘍性大腸炎(ulcerative colitis ; UC)の治療は免疫統御療法や抗TNF-α療法の保険適用など大きな飛躍を遂げた.白血球系細胞除去療法(cytapheresis ; CAP)も,2010年には,UCに対して,週における治療スケジュールの回数制限がなくなり,CAPのintensive therapyが可能となった.当院の検討でも,GMA,LCAPとも副作用なく,週1回法と同程度の割合の寛解導入がより速やかに可能であった.CAPのintensive療法は安全に効果を出すことが可能であるので,適用症例には積極的に行うべきと考える.
The therapeutic strategy for steroid refractory active UC(ulcerative colitis)has expanded with the appearance of several novel options, such as thioprine and biologics. Also, intensive CAP(cytapheresis)has been accepted by the social health insurance scheme from 2010 in Japan. In the present report, we have evaluated the clinical efficiency of intensive, performed-twice-a-week CAP in our hospital. The UC patients who were treated with the intensive regimen responded faster than those treated by conventional weekly CAP. Our results might encourage other doctors to perform CAP therapy with the intensive regimen.
Copyright © 2011, Igaku-Shoin Ltd. All rights reserved.